Jue Wang
The University of Sydney(AU)Fujian Medical University(CN)Shanghai Medical College of Fudan University(CN)China Meteorological Administration(CN)Wenzhou University(CN)Army Medical University(CN)Henan University of Science and Technology(CN)Shanxi University(CN)Shanghai Jiao Tong University(CN)Liaocheng University(CN)Kunming Medical University(CN)Concord Repatriation General Hospital(AU)Daping Hospital(CN)Tongren Hospital(CN)Cell Technology (China)(CN)First Affiliated Hospital of Kunming Medical University(CN)First Affiliated Hospital of Chongqing Medical University(CN)Hunan Province Chest Hospital(CN)Beijing University of Agriculture(CN)Hangzhou Hospital of Traditional Chinese Medicine(CN)Obstetrics and Gynecology Hospital of Fudan University(CN)Jiangsu Hengrui Medicine (China)(CN)Wenzhou Institute of Industrial Science(CN)Fujian Provincial Cancer Hospital(CN)Tang Du Hospital(CN)Wenzhou Institute of Technology Testing & Calibration(CN)Tongji Hospital(CN)Huazhong University of Science and Technology(CN)Nanjing Medical University(CN)Chongqing Medical University(CN)Bohai University(CN)Air Force Medical University(CN)
Publications by Year
Research Areas
CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Erythrocyte Function and Pathophysiology
Most-Cited Works
- → Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study(2018)295 cited
- → Calcium in Red Blood Cells—A Perilous Balance(2013)246 cited
- → Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study(2020)215 cited
- → FN18-CRM9 IMMUNOTOXIN PROMOTES TOLERANCE IN PRIMATE RENAL ALLOGRAFTS1(1997)213 cited
- → Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis(2016)211 cited
- → A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma(2021)206 cited